Publications

Publications

Filter Results: (1) Arrow Down

Show Results For

SymlinRemove Symlin →

Page 1 of 1 Result

Are you looking for?

→Search All HBS Web
  • December 2008 (Revised October 2013)
  • Case

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
Related

Are you looking for?

→Search All HBS Web